
RGNT P/E Ratio
P/E Ratio as of Dec 12, 2025: -6.25
Average-5.57
Median-6.23
Minimum-6.53
Maximum-1.82
-6.25
The P/E ratio for RGNT is -6.25 as of Dec 12, 2025. This represents a increase of 4,066.67% compared to its 12-month average P/E ratio of -0.15. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Regentis Biomaterials Ltd/Israel P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Regentis Biomaterials Ltd/Israel’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Regentis Biomaterials Ltd/Israel to industry peers.
Regentis Biomaterials Ltd/Israel P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Regentis Biomaterials Ltd/Israel’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Regentis Biomaterials Ltd/Israel to industry peers.
RGNT P/E Ratio Insights
See Regentis Biomaterials Ltd/Israel’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in RGNT
Order type
Buy in
Order amount
Est. shares
0 shares
RGNT P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 5, 2025 | $7.49 | -1.82 |
RGNT End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -6.25 | — |
FAQs About Regentis Biomaterials Ltd/Israel (RGNT) P/E ratio
The latest P/E ratio of RGNT is -6.25, as of Dec 12, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Regentis Biomaterials Ltd/Israel’s last 12-month average P/E ratio is -0.15, compared to its current P/E ratio of -6.25. This reflects a increase of 4,066.67%.
Regentis Biomaterials Ltd/Israel’s current P/E ratio of -6.25 is higher than its last 12-month average P/E of -0.15. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Regentis Biomaterials Ltd/Israel’s average P/E ratio over the last 3 years is -0.05. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Regentis Biomaterials Ltd/Israel’s average P/E ratio over the last 5 years is -0.03. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.